Explore daily insights on
Legend Biotech Surges 42% to Break Losing Streak on 100% Lymphoma Trial Success
- Legend Biotech shares rallied strongly after the company announced a 100% response rate in a Phase 1 trial for its experimental lymphoma treatment.
- The stock soared 42.22% to close at $36.28 on June 2, breaking a four-day losing streak on 5.9 times its average trading volume.
- Perfect efficacy results in early-stage trials bolster confidence in the company's next-generation CAR-T platform and its potential to treat aggressive cancers.
Supporting datasets
Supporting queries
To surface this insight, Baselight ran 4 queries across its structured data. Each one is reproducible — open it, read the SQL, and rerun it yourself.
Conclusion
LEGN close rose from $25.51 (June 1) to $36.28 (June 2) (+42.22%). Volume of 14,616,300 vs. 20-day average of 2,465,799 (5.9x ratio).